US Bancorp DE boosted its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 94.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 758 shares of the specialty pharmaceutical company’s stock after buying an additional 368 shares during the period. US Bancorp DE’s holdings in Jazz Pharmaceuticals PLC were worth $118,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in JAZZ. Vanguard Group Inc. raised its position in Jazz Pharmaceuticals PLC by 3.5% in the first quarter. Vanguard Group Inc. now owns 4,523,315 shares of the specialty pharmaceutical company’s stock valued at $656,469,000 after buying an additional 152,065 shares during the last quarter. BlackRock Inc. raised its position in Jazz Pharmaceuticals PLC by 3,163.9% in the first quarter. BlackRock Inc. now owns 3,215,159 shares of the specialty pharmaceutical company’s stock valued at $466,615,000 after buying an additional 3,116,652 shares during the last quarter. Janus Capital Management LLC raised its position in Jazz Pharmaceuticals PLC by 46.8% in the first quarter. Janus Capital Management LLC now owns 1,470,245 shares of the specialty pharmaceutical company’s stock valued at $213,367,000 after buying an additional 468,940 shares during the last quarter. Bank of New York Mellon Corp raised its position in Jazz Pharmaceuticals PLC by 3.2% in the first quarter. Bank of New York Mellon Corp now owns 1,447,760 shares of the specialty pharmaceutical company’s stock valued at $210,114,000 after buying an additional 44,973 shares during the last quarter. Finally, Westfield Capital Management Co. LP raised its position in Jazz Pharmaceuticals PLC by 9.4% in the first quarter. Westfield Capital Management Co. LP now owns 1,377,214 shares of the specialty pharmaceutical company’s stock valued at $199,875,000 after buying an additional 117,825 shares during the last quarter. Hedge funds and other institutional investors own 88.24% of the company’s stock.

Jazz Pharmaceuticals PLC (NASDAQ JAZZ) traded down 0.5315% during trading on Wednesday, reaching $145.0848. 230,314 shares of the company’s stock were exchanged. The stock has a market cap of $8.71 billion, a PE ratio of 22.3482 and a beta of 1.10. The firm has a 50 day moving average of $152.07 and a 200-day moving average of $148.41. Jazz Pharmaceuticals PLC has a 12 month low of $95.80 and a 12 month high of $163.75.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last announced its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.85 by $0.13. Jazz Pharmaceuticals PLC had a net margin of 25.69% and a return on equity of 22.75%. The business had revenue of $394.39 million for the quarter, compared to analyst estimates of $410.83 million. During the same period in the prior year, the company earned $2.67 earnings per share. The company’s quarterly revenue was up 3.5% on a year-over-year basis. On average, equities research analysts anticipate that Jazz Pharmaceuticals PLC will post $10.88 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This report was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another site, it was stolen and reposted in violation of international copyright & trademark law. The original version of this report can be read at https://www.thecerbatgem.com/2017/08/30/us-bancorp-de-has-118000-stake-in-jazz-pharmaceuticals-plc-jazz.html.

JAZZ has been the subject of several analyst reports. Wells Fargo & Co restated an “outperform” rating and set a $177.00 price target (down previously from $178.00) on shares of Jazz Pharmaceuticals PLC in a report on Thursday, August 10th. BidaskClub downgraded shares of Jazz Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a research report on Thursday, August 3rd. Zacks Investment Research downgraded shares of Jazz Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a research report on Tuesday, May 2nd. Vetr raised shares of Jazz Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $151.11 price objective for the company in a research report on Tuesday, June 6th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and set a $182.00 price objective on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday, June 7th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and nineteen have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $180.96.

In related news, Director Rick E. Winningham sold 5,000 shares of the company’s stock in a transaction dated Thursday, June 1st. The stock was sold at an average price of $150.00, for a total transaction of $750,000.00. Following the transaction, the director now directly owns 10,391 shares of the company’s stock, valued at approximately $1,558,650. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Paul L. Berns sold 662 shares of the company’s stock in a transaction dated Friday, August 11th. The shares were sold at an average price of $142.37, for a total value of $94,248.94. Following the transaction, the director now directly owns 6,599 shares in the company, valued at $939,499.63. The disclosure for this sale can be found here. Insiders have sold a total of 12,917 shares of company stock worth $1,973,227 over the last ninety days. 4.30% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals PLC Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Institutional Ownership by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Stock Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.